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ABSTRACT 24 
Background: Combination inhaled therapy with long-acting β2-agonist (LABA) and corticosteroid 25 
is beneficial in treating asthma and chronic obstructive pulmonary disease (COPD).  26 
Objective: In asthma, LABAs enhance glucocorticoid receptor (GR) nuclear translocation in the 27 
presence of corticosteroids. Whether this biological mechanism occurs in COPD, a relatively 28 
corticosteroid-resistant disease, is uncertain. 29 
Methods: Eight patients with mild/moderate COPD participated in a double-blind, placebo-30 
controlled, crossover study and inhaled single-doses of; fluticasone propionate (FP)-100μg, FP-31 
500μg, salmeterol(SLM)-50μg and combination FP-100μg+SLM-50μg. One hour post-inhalation 32 
sputum was induced, nuclear proteins isolated from purified macrophages and levels of 33 
activated nuclear GR quantified using a GR-GRE ELISA-based assay. 34 
Results: Nuclear GR significantly increased after FP-500μg (p<0.01), but not after FP-100μg or 35 
SLM-50μg, compared to placebo. Interestingly, SLM in combination with FP-100μg increased 36 
nuclear GR levels equivalent to those of FP-500μg alone. This was significantly greater than 37 
either FP-100μg (p<0.05) or SLM-50μg (p<0.01) alone.  In vitro in a human macrophage cell line, 38 
SLM (10-8M) enhanced FP (10-9M)-induced mitogen-activated protein kinase phosphatase-1 39 
(MKP-1) mRNA (5.8±0.6 vs. 8.4±1.1 x 10-6 copies, p<0.05) and 2xGRE-luciferase reporter gene 40 
activity (250.1±15.6 vs. 103.1±23.6 fold induction, p<0.001). Addition of SLM (10-9M) to FP (10-41 
11M) significantly enhanced FP-mediated suppression of IL-1β-induced CXCL8 (p<0.05).  42 
Conclusion: Addition of SLM-50μg to FP-100μg, enhanced GR nuclear translocation equivalent 43 
to that seen with a five-fold higher dose of FP in sputum macrophages from COPD patients. This 44 
may account for the superior clinical effects observed in COPD of combination 45 
LABA/corticosteroid treatment compared to either as monotherapy. 46 
 47 
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CLINICAL INFORMATION  48 
Sputum macrophages from COPD patients are relatively corticosteroid insensitive. Inhaled 49 
salmeterol and fluticasone propionate greatly enhanced glucocorticoid receptor activation in 50 
sputum macrophages from COPD patients. 51 
 52 
 53 
CAPSULE SUMMARY  54 
Combination therapy with inhaled long-acting β2-agonist and corticosteroid improves clinical 55 
outcomes in COPD and biologically, enhanced glucocorticoid receptor activation in sputum 56 
macrophages may partly explain this phenomenon.  57 
 58 
 59 
KEYWORDS: long-acting β2-agonist, corticosteroid, transcription factor, glucocorticoid receptor, 60 
sputum, COPD, macrophage  61 
 62 
63 
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ABBREVIATIONS 64 
COPD  Chronic obstructive pulmonary disease 65 
FCS  Fetal calf serum 66 
FP  Fluticasone propionate  67 
FEV1  Forced expiratory volume in one-second 68 
GR  Glucocorticoid receptor 69 
GRE  Glucocorticoid response element 70 
HBSS  Hanks' buffered saline solution  71 
ICS  Inhaled corticosteroids 72 
LABAs  Long-acting β2-agonists  73 
MKP-1  Mitogen-activated protein kinase phosphatase-1 74 
PBMCs  Peripheral blood mononuclear cells 75 
SLM  Salmeterol xinafoate 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
 86 
 87 
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INTRODUCTION 88 
It is well-established in asthmatic patients that the addition of long-acting β2-agonist (LABA) to 89 
inhaled corticosteroids (ICS) provides more effective disease control than monotherapy with ICS 90 
[1-4]. Indeed, with recent concerns regarding the safety of LABA monotherapy in the treatment 91 
of asthma, current guidance supports fixed dose combinations of LABA/ICS therapy from a 92 
single inhaler [5-7]. Chronic obstructive pulmonary disease (COPD) is also characterized by 93 
chronic airways inflammation, but unlike asthma, ICS treatment on its own has relatively little 94 
effect on the accelerated decline in lung function seen in COPD patients [8,9]. However in 95 
contrast, several large clinical trials of combination LABA/ICS therapy in patients with stable 96 
COPD have shown better control of respiratory symptoms, lung function, quality of life, and 97 
exacerbations with no greater risk of side-effects, compared to the use of either ICS alone or 98 
LABA alone (10-13). Recent studies have demonstrated the effectiveness of LABA/ICS 99 
combination therapy in reducing COPD morbidity and mortality compared with ICS treatment 100 
alone (14, 15). 101 
 102 
The scientific rationale to explain the disproportionately superior clinical efficacy achieved by 103 
the addition of LABAs to ICS in the treatment of asthma and COPD is being addressed, and 104 
elucidating the underlying molecular mechanisms may help identify novel therapeutic targets 105 
(16, 17). Combination therapy with SLM/FP reduces sputum differential cell counts, sputum 106 
neutrophils and eosinophils, bronchial CD45+, CD8+ and CD4+ cells, and cells expressing genes 107 
for tumor necrosis factor-α and interferon-γ in comparison to placebo (18). These anti-108 
inflammatory effects were also accompanied by improvements in the pre-bronchodilator forced 109 
expiratory volume in one-second (FEV1). Treatment with SLM/FP combination has also been 110 
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shown to reduce tissue CD8+ and CD68+ cells compared with placebo, whereas no effect was 111 
observed with FP alone (19).  112 
 113 
It has been proposed LABAs may have anti-inflammatory properties similar to ICS (20, 21). 114 
Studies show LABAs enhance corticosteroid-dependent anti-inflammatory effects, and the 115 
biological mechanism for this may be through ligand-independent priming of the glucocorticoid 116 
receptor (GR) (22). The cellular actions of corticosteroids are mediated by intracellular GRs, 117 
which after binding to corticosteroid, translocate from the cell cytoplasm into the nucleus 118 
where they mediate corticosteroid-dependent effects (23). Enhanced GR activation by LABAs 119 
has been demonstrated in vitro in human lung fibroblasts and smooth muscle cells (22, 24), in 120 
human neutrophils (25), and ex vivo in the sputum of patients with asthma (17). However, it is 121 
unknown whether LABAs cause GR translocation after ICS therapy in COPD patients, as this 122 
disease is much less responsive to the effects of corticosteroids compared to asthma (26). 123 
Indeed, macrophages from COPD patients have been shown to exhibit a poor anti-inflammatory 124 
response to corticosteroids in vitro compared to cells from healthy smokers and non-smokers 125 
(21). 126 
 127 
In this study, we examined the effect of SLM/FP combination treatment on GR-glucocorticoid 128 
response element (GRE) binding in the nucleus of macrophages isolated from the induced 129 
sputum of patients with COPD. Importantly, we used inhaled drug doses used in the clinic. Our 130 
aim was to determine whether GR activation in response to corticosteroid therapy was 131 
enhanced by a LABA and whether this had any functional effects. As reduced nuclear 132 
translocation of GR contributes to corticosteroid insensitivity (16, 26), we hypothesized that the 133 
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LABA, salmeterol, could contribute to improve corticosteroid insensitivity in cells from COPD 134 
patients. 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
 148 
 149 
 150 
 151 
 152 
 153 
 154 
 155 
 156 
 157 
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METHODS 158 
Subjects 159 
Eight patients diagnosed with moderate COPD (GOLD stages 2 and 3 (27)), <12% reversibility in 160 
FEV1 and a smoking history of >10 pack-years, participated in a randomized, double-blind, 161 
placebo-controlled cross-over study. All patients were aged between 40 – 80 years and were not 162 
taking either ICS or LABAs (Table 1). At each study-visit, patients’ FEV1 was required to be within 163 
15% of their screening FEV1 value to control for differences in airway function and inflammation 164 
between visits. Patients were allowed to take the bronchodilators tiotropium bromide and/or 165 
albuterol during the study, but none of the subjects were treated with ICS or LABAs for at least 166 
one month preceding the start of the study. 167 
 168 
Study design 169 
Single actuations of fluticasone propionate (FP)-100μg, FP-500μg, salmeterol xinafoate (SLM)-170 
50μg, combination therapy FP/SLM 100μg/50μg (Seretide, GlaxoSmithKline, Stevenage, U.K.) 171 
or placebo were delivered via a metered dose inhaler and spacer, separately at each study visit 172 
Sputum was induced 60 minutes after drug inhalation and peripheral blood samples were also 173 
taken at this time point. The study was approved by the Ethics Committee of the Royal 174 
Brompton & Harefield Hospitals National Health Service Trust, and all subjects gave written 175 
informed consent. 176 
 177 
There was a minimum washout period between treatments of seven days to prevent any 178 
crossover effects. All patients were randomised (pre-assigned by picking balls out of a bag) to 179 
determine the order of treatment. In this scenario, there were 24 possible crossover orders, and 180 
with 8 subjects, there would have been possible treatment orders that were not received. 181 
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However, the sample size of 8 subjects was ethically chosen based on our previous study (17), 182 
where 7 subjects received 5 treatments, which was sufficient to detect statistical differences 183 
between ICS alone vs. LABA/ICS combination in asthmatic subjects. 184 
 185 
Sputum induction and processing 186 
Sputum induction was performed as previously described and processed within one hour of 187 
collection (17). Briefly, sputum was filtered (70μm filter) and centrifuged (1600rpm for 5 min) to 188 
obtain a cell pellet. Cells were resuspended in full RPMI-1640 media (Sigma-Aldrich), 189 
supplemented with 1% L-glutamine, 10% fetal calf serum (FCS; Invitrogen Ltd, Carlsbad, CA), 100 190 
U/ml penicillin and 100μg/ml streptomycin (Sigma-Aldrich). Total cell count (Kimura stain) and 191 
viability (Trypan blue exclusion) were determined before cytospins were undertaken. 192 
 193 
Ex-vivo stimulation of sputum macrophages 194 
Sputum macrophages were isolated from whole sputum using plastic adherence at a cell density 195 
of 0.5x106 cells/ml for 4 h in a 5% CO2 humidified atmosphere at 37°C. Non-adherent cells were 196 
removed and macrophages resuspended in charcoal-stripped RPMI-1640 minimal media (1% L-197 
glutamine and 0.5% FCS) overnight, before being exposed to SLM (10-7M), FP (10-9M), or a 198 
combination of both, for 60 min. The same number of macrophage cells in culture were seeded 199 
for each treatment visit and utilised for each of the experiments, standardised to a cell density 200 
of 0.5x106 cells/ml. 201 
 202 
Isolation of blood cells 203 
Venous blood (80 ml) was diluted 1:1 with Hanks' buffered saline solution (HBSS, Invitrogen) and 204 
layered on Ficoll-Hypaque-Plus (Amersham plc, Amersham, UK). After centrifugation (30 min at 205 
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1,100 x g and 18°C), peripheral blood mononuclear cells (PBMCs) were collected, washed, and 206 
centrifuged (250 x g for 10 min). PBMCs were resuspended in culture media and counted using 207 
Kimura dye.  208 
 209 
Nuclear extraction 210 
Nuclear and cytoplasmic fractions were extracted using a Nuclear Extraction kit (Active Motif, 211 
Carlsbad, CA). Briefly, cells were resuspended in hypotonic buffer, vortexed and incubated on 212 
ice for 15 min to extract the cytoplasmic fraction. Thereafter, the remaining nuclear pellets were 213 
resuspended in complete lysis buffer for 30 min on ice. The suspension was centrifuged 214 
(14000rpm, 10 min, 4ºC) and the nuclear fraction obtained. The quality and purity of the nuclear 215 
extract was determined by Western Blotting (Figure 1A). 216 
 217 
GRE binding assay 218 
GR activation was determined with a GR-GRE TransAM kit (Active Motif, Frixensart, Belgium) 219 
according to the manufacturer’s instructions and nuclear GR-GRE binding was determined. 220 
Briefly, 5μg of nuclear extract of each sample was added to a well. Each well contained multiple 221 
copies of a specific double-stranded oligonucleotide which activated GR binds to at its 222 
consensus binding site. We confirmed using Western blotting in U937 cells that incubation with 223 
the positive control, fluticasone propionate, led to an increase in nuclear GR, which correlated 224 
to an induction in GR-GRE binding, relative to the negative control of untreated cells (Figure 1B 225 
& C).  226 
 227 
Confocal microscopy 228 
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Sputum macrophages were seeded onto glass coverslips in 6-well plates and allowed to attach 229 
at 37°C. The cells were fixed with 4% paraformaldehye in phosphate buffered saline (PBS) for 10 230 
min at 37°C and washed three times with PBS. Cells were then permeabilized with 0.2% Triton 231 
X-100 (Sigma-Aldrich, Poole, UK) for 5min and then incubated with primary anti-GR antibody (H-232 
300, Santa Cruz Biotechnology, CA, USA) for 3 hours followed by 30 min with secondary 233 
antibody Alexa 488 (Invitrogen). Coverslips were washed three times with PBS, rinsed in distilled 234 
water and immediately dried. Prolong Antifade 4’, 6-diamidino-2-phenylindole dihydrochloride 235 
(DAPI) solution (Invitrogen) was added to delineate the nuclear boundary in each cell and help 236 
define the distribution of GR protein (green) within the respective subcellular compartments 237 
(Figure 2). Coverslips were mounted onto slides and allowed to dry for 4 hours before analysis 238 
using confocal microscopy with imaging software (Leica Confocal Software Lite, Heidelberg, 239 
Germany).  240 
 241 
Cell Culture 242 
U937 cells (ATCC, Rockville, MD) were maintained in RPMI-40 medium (Invitrogen), 243 
supplemented with L-glutamine (1%, Invitrogen) and fetal calf serum (FCS, 10%, Invitrogen), and 244 
were differentiated as previously described (28).  After washing with HBSS, cells were allowed to 245 
recover in medium supplemented with 1% L-glutamine and 0.1% charcoal-stripped FCS for 48 246 
hours before experiments.  247 
 248 
MKP-1 mRNA expression 249 
Differentiated U937 cells were cultured in RPMI supplemented with 0.1% charcoal-stripped-FCS 250 
and L-glutamine (1%) for 24 h before treatment. Total RNA was isolated from cells using an 251 
RNeasy Kit (Qiagen, Hilden, Germany). cDNA was synthesised from 1μg of total RNA with the 252 
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Qiagen Quantitect Kit (Qiagen) according to the manufacturer’s protocol. Expression of 253 
mitogen-activated protein kinase phosphatase-1 (MKP-1) mRNA was quantified by RT-qPCR with 254 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, US). Primers are shown in 255 
Table 2. MKP-1 mRNA levels were normalized to an endogenous reference GAPDH and absolute 256 
quantification was determined by using known standards of MKP-1. MKP-1 standards were 257 
produced from PCR products containing the target sequence from U937 monocytes. The copy 258 
number of the standards was determined by measuring the concentration using a 259 
spectrophotometer. 260 
 261 
GR reporter gene assay 262 
Differentiated U937 cells were transfected with GRE-luciferase and β-galactosidase plasmids as 263 
previously described and GR transactivation determined by luciferase assay as previously 264 
described (17). 265 
 266 
CXCL8 enzyme-linked immunosorbent assay (ELISA) 267 
Serum-starved U937 cells were incubated with IL-1β for 30 min, followed by FP and SLM alone 268 
and in combination for 16 hours. Subsequently, extracellular concentrations of CXCL8 were 269 
measured with human CXCL8 Duoset ELISA kits (R&D Systems Europe, Abingdon, UK) according 270 
to the manufacturer’s instructions. 271 
 272 
Statistical analysis 273 
In the in vivo study, as sputum cells are not normally distributed, a non-Gaussian distribution 274 
was adopted and data were analysed using non-parametric statistical analyses using the PC 275 
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analysis package Graph Pad Prism (Graph Pad Prism, San Diego, CA). Results were analyzed 276 
using Friedman analysis of variance (ANOVA) including factors for period, treatment, and 277 
multiple comparisons, and applying Bonferroni’s post-test correction. Comparisons between 278 
treatments were made using the Wilcoxon matched-pairs signed rank sum test. A p value of less 279 
than 0.05 was considered statistically significant. For the difference between treatment groups 280 
in the in vitro data, analyses were undertaken using the Mann-Whitney test for comparison of 281 
two unpaired groups with Graph Pad Prism software. A p value of less than 0.05 was considered 282 
statistically significant. 283 
 284 
 285 
 286 
 287 
 288 
 289 
 290 
 291 
 292 
 293 
 294 
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RESULTS 295 
Patient characteristics 296 
The mean age of the eight patients (6 female) was 65 ± 8 years and the mean post-297 
bronchodilator FEV1 was 72 ± 12% of predicted (Table 1).  No patient showed >12% reversibility 298 
to albuterol, was atopic, or had a previous history of asthma. Median % sputum cell counts are 299 
shown in Table 1 averaged from different study visits across all patients, and most patients had 300 
high levels of neutrophilia. The percentage of sputum macrophages obtained varied between 301 
visits within each patient (range -6.7% to +12.2%) compared to the sample taken at visit 1. 302 
However, the amount of protein extracted from the isolated macrophage nuclear extracts for 303 
the GR-GRE assay was normalised to be the same for all samples from all patients for all visits, 304 
irrespective of the variability in the sputum macrophages yielded following sputum induction, 305 
and this was 5µg.  306 
 307 
Effect of LABA and corticosteroid on GR-GRE binding in sputum cells in vivo 308 
GR-GRE binding levels in the nuclei of macrophages obtained from induced sputum were not 309 
significantly altered at 60 minutes following inhalation of FP-100μg or SLM-50μg compared to 310 
placebo (Figure 3A).  In contrast, FP-500μg significantly increased GR-GRE binding levels 2.2-fold 311 
compared to placebo (0.607 ± 0.089 vs. 0.274 ± 0.038 absorbance units, p<0.01) and induction 312 
of GR-GRE binding was significantly greater with FP-500μg compared to that observed with FP-313 
100μg (0.607 ± 0.089 vs. 0.310 ± 0.028 absorbance units, p<0.05). Combination treatment of FP-314 
100μg with SLM-50μg increased nuclear GR-GRE levels to similar levels to those seen with FP-315 
500μg (respectively 0.598±0.061 vs. 0.607 ± 0.089, p = NS). This effect observed with the 316 
combination treatment was significantly greater than that seen with either placebo (p<0.01), FP-317 
100μg alone (p<0.05) or SLM-50μg alone (p<0.01).  The addition of SLM-50μg to FP-100μg as 318 
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combination treatment, achieved an enhancement of GR activation in sputum macrophages 319 
from patients with COPD that was equivalent to that observed with a five-fold increase in the 320 
dose of FP. That is, combination therapy allowed a five-fold reduction in the inhaled 321 
corticosteroid dose, yet achieved the same biological effects. Confocal microscopy documented 322 
the correlation between the glucocorticoid receptor GRE binding assay and glucocorticoid 323 
receptor nuclear translocation in that, treatment with corticosteroid (FP-500μg) led to GR 324 
nuclear translocation in sputum macrophage cells (Figure 2). 325 
 326 
Effect of LABA and corticosteroid on GR-GRE binding in PBMCs in vivo 327 
The levels of GR-GRE binding in PBMCs were measured 60 minutes after inhalation of the drugs 328 
(Figure 3B).  None of the active treatments had an effect on GR-GRE binding levels and these 329 
levels did not differ significantly from those obtained with placebo.  330 
 331 
Effect of LABA and corticosteroid on GR-GRE binding in sputum cells ex vivo 332 
Sputum macrophages were isolated by adherence to plastic, allowed to recover for 24 h before 333 
stimulation with SLM (10-7M), FP (10-9M) or a combination of both for 60 minutes. FP 334 
significantly enhanced nuclear GR-GRE binding compared to control unstimulated cells (0.506 ± 335 
0.042 vs. 0.252 ± 0.038 absorbance units, p<0.01).  Salmeterol alone had no significant effect on 336 
GR-GRE binding levels compared to control (Figure 4). However, the addition of SLM to FP 337 
significantly enhanced the ability of FP alone (10-9M) to stimulate GR-GRE binding (0.710 ± 0.073 338 
vs. 0.506 ± 0.042 absorbance units, p<0.05).  339 
 340 
Induction of MKP-1 mRNA in macrophage-like U937 cells 341 
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FP (10-9M) alone significantly induced MKP-1 mRNA expression after 2 h compared to the levels 342 
seen in control unstimulated cells (5.8 ± 0.6 x 10-6 vs. 6.4±2.5 x 10-8 copies, p<0.001), whilst SLM 343 
(10-8M) alone had no effect (3.2 ± 0.6 x 10-8 copies, p=NS) (Figure 5A). However, upon addition 344 
to FP, SLM significantly enhanced FP-induced MKP-1 mRNA (5.8 ± 0.6 vs. 8.4 ± 1.1 x 10-6 copies, 345 
p<0.05). 346 
 347 
Induction of GRE-luciferase activity by LABA and corticosteroid in macrophage-like U937 cells 348 
Salmeterol (10-8M) alone had no significant effect on a 2xGRE-luciferase reporter gene activity 349 
compared to control unstimulated cells (1.0 ± 0.6 vs. 1.5 ± 0.4 fold induction, p=NS) (Figure 5B). 350 
In contrast, FP (10-9M) significantly enhanced GRE-luciferase activity compared to control (103.1 351 
± 23.6 fold induction, p<0.05). Yet, the addition of SLM to FP resulted in a highly significant 352 
increase in GRE-luciferase activity compared to that seen with FP alone (250.1 ± 15.6 vs. 103.1 ± 353 
23.6 fold induction, p<0.001).  354 
 355 
Effect of LABA and corticosteroid on IL-1β-induced CXCL8 in macrophage-like U937 cells  356 
FP (10-11M) and (10-9M) significantly suppressed IL-1β-induced CXCL8 (28.3 ± 3.2 and 71.2 ± 3.1 357 
% respectively, p<0.01), whilst SLM (10-9M) alone had no considerable effect (Figure 6). 358 
However, the addition of SLM (10-9M) to FP (10-11M) significantly enhanced FP-mediated 359 
suppression of IL-1β-induced CXCL8 (46.7 ± 4.8   vs. 28.3 ± 3.2 %, p<0.05). 360 
 361 
 362 
 363 
 364 
 365 
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DISCUSSION 366 
Our study shows that nuclear levels of activated GR in macrophages obtained from the induced 367 
sputum of patients with COPD increased following single-dose inhalation treatment with high-368 
dose fluticasone propionate (FP)-500μg, but not after low-dose FP-100μg alone or salmeterol 369 
(SLM)-50μg alone. Most importantly, the addition of SLM-50μg to low-dose FP-100μg increased 370 
activated GR levels equivalent to those seen with high-dose FP-500μg. That is, in COPD patients, 371 
addition of salmeterol to a low-dose of FP achieved an enhancement of GR nuclear 372 
translocation equivalent to that observed with a five-fold higher corticosteroid dose. Consistent 373 
with our in vivo patient data, we were able to demonstrate that salmeterol significantly 374 
enhanced the ability of FP to induce GR activation in sputum macrophages ex vivo and enhanced 375 
FP-induction of MKP-1 mRNA and 2xGRE reporter gene activity in a human cultured 376 
macrophage cell line in vitro. Additionally, we were able to show a functional anti-inflammatory 377 
effect of combination therapy in that salmeterol significantly enhanced FP-mediated 378 
suppression of IL-1β-induced CXCL8 in macrophage-like U937 cells. 379 
 380 
When LABAs were introduced as an add-on therapy to inhaled corticosteroids, the magnitude of 381 
their clinical beneficial effect in the control of asthma, and in COPD, was not predicted. The role 382 
of LABAs was seen purely as bronchodilatation without any appreciable effect on bronchial 383 
inflammation. In asthma, LABAs combined with corticosteroids produced a better effect on 384 
symptoms (1, 3), lung function (29), exacerbation rates (30) and health status (31) than 385 
expected. Adding LABA to low-dose ICS was observed to be more effective than increasing the 386 
dose of corticosteroids (1, 29, 30, 32) and asthma guidelines were updated to reflect these 387 
findings (33). 388 
 389 
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The beneficial effects of the LABA/ICS combination have also been observed in COPD patients, 390 
where they are now an established treatment. The TORCH (TOwards a Revolution in COPD 391 
Health) study demonstrated reductions in exacerbation rates, improvements in health status 392 
and lung function with SLM/FP combination compared to placebo in COPD patients (15). The 393 
study observed a relative reduction in mortality of 17% over three years for patients receiving 394 
SLM/FP, although this just failed to reach statistical significance. A subsequent Cochrane review 395 
observed survival benefits with combination therapy compared both to placebo (34) and to ICS 396 
alone (14). In vivo studies using bronchial biopsies have generated further supporting evidence 397 
for complementary interactions between LABAs and corticosteroids on airway inflammation and 398 
pathology in COPD patients (18, 19). 399 
 400 
Our data reveal a complementary interaction between the LABA (salmeterol) and corticosteroid 401 
(fluticasone propionate) in that the combination therapy has a greater anti-inflammatory effect 402 
than either drug alone and was also steroid sparing; allowing a five-fold reduction in the inhaled 403 
corticosteroid dose, yet achieving the same biological effects. Indeed our data support the 404 
postulate that changes in the anti-inflammatory effects with combination therapy may account 405 
for the improvements in the rate of decline in lung function seen in the TORCH study (35).  406 
 407 
We confirm that sputum macrophages from COPD patients are less sensitive to corticosteroid 408 
action compared to those obtained from asthmatic subjects (36, 37). In our previous study 409 
examining the effect of corticosteroid (FP) on GR activation in sputum macrophages from 410 
mild/moderate asthmatic subjects we demonstrated that 60 minutes post-treatment, FP-100μg 411 
significantly enhanced GR nuclear translocation (17). Here we show that only the higher dose of 412 
FP-500μg had an effect on GR-GRE binding. These data suggest that GR-GRE binding in sputum 413 
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macrophages may be a good biomarker for corticosteroid actions. As in our previous study (17), 414 
we were able to detect a quantifiable degree of basal GR-GRE binding in sputum macrophages 415 
in the placebo-treated patients (Figure 3) and this level of GR activation was maintained for at 416 
least 24 hours in culture. Since none of the patients in this study were exposed to exogenous 417 
inhaled or oral corticosteroids this activation must reflect the action of endogenous 418 
corticosteroids. 419 
 420 
Consistent with our in vivo patient data, our in vitro experiments, showed salmeterol enhanced 421 
the ability of low concentrations of FP to induce GRE-luciferase activity and switch on MKP-1 422 
expression in macrophage-like U937 cells. Similar data for enhanced induction of glucocorticoid-423 
responsive genes in the presence of a LABA such as MKP-1 and glucocorticoid inducible leucine 424 
zipper (GILZ) has been reported in airway epithelial cells and smooth muscle cells (38). Our 425 
results are consistent with literature that suggest the enhanced effects may result from the 426 
ability of LABAs to promote GR nuclear translocation in human lung fibroblasts (22), airway 427 
smooth muscle cells (24, 39, 40) and in sputum cells from asthmatic patients (17). This 428 
enhancement of GR translocation achieved by LABAs when added to corticosteroids is likely to 429 
underlie some of the clinical benefits seen with combination therapy. Additionally, we 430 
demonstrated that the enhancement of GR translocation with combination therapy was 431 
associated with a functional anti-inflammatory effect; in that, salmeterol significantly enhanced 432 
FP-mediated suppression of IL-1β-induced CXCL8 in U937 cells.  433 
 434 
We were unable to assess the anti-inflammatory properties of the combination treatment in 435 
sputum macrophages in vivo due to limitations in cells numbers and ethical considerations 436 
regarding repeated sputum induction in patients. Future experiments examining gene 437 
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expression profiles in sputum macrophages 4 hours after inhaled drugs will provide evidence for 438 
additional genes that are regulated in a similar manner to those described here. A role for other 439 
aspects of GR activation including GR post-translational modifications and the activity of GR 440 
chaperone proteins is difficult to rule out as potential modulators of GR-GRE binding. An 441 
experimental clinical patient study specifically designed to address these points would be 442 
needed. In contrast to our observations in sputum macrophages, the levels of activated GR in 443 
the nuclei of PBMCs did not change significantly after any treatment. This is likely to be due to 444 
peripheral blood levels of the study medications being too low after a single-dose inhalation to 445 
exert a measurable effect on the biological machinery of GR translocation. It would be 446 
interesting to see if a measurable effect is achieved after a more prolonged course of treatment. 447 
 448 
The marked effect of LABAs on GR translocation in vitro and in vivo, in asthmatics and in COPD 449 
patients warrants further investigation, and elucidation of the precise molecular mechanisms of 450 
how LABAs (which acting extracellularly via the β2 receptor) are able to influence translocation 451 
of cytoplasmic GRs. Altered phosphorylation, ‘priming’ of the GR increasing its tendency to 452 
translocate without the need for its natural ligand has been proposed (41, 42). Recently we have 453 
shown that LABA increase GR nuclear translocation through the activation of a phosphatase 454 
PPA2, which dephosphorylates hyperphosphorylated GR (43). 455 
 456 
In conclusion, we report here for the first-time that a LABA in combination with a low-dose of 457 
ICS enhances GR-GRE binding in vivo in COPD patients as effectively as a five-fold higher dose of 458 
ICS alone. This suggests LABAs may play an important role in the benefits clinically seen with 459 
combination therapy. Our data has clinical relevance to the use of combination inhalers in view 460 
of the reduced sensitivity to ICS in COPD. Further studies are needed to address whether these 461 
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differences are maintained following chronic treatment of LABAs with ICS in COPD patients, and 462 
whether this results in an alteration in sputum cytokine profiles in vivo. 463 
 464 
 465 
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TABLES 588 
TABLE 1.  589 
Patient characteristics 590 
Age (years) 65 ± 8 
Gender 2M/6F 
GOLD stage 2 stage 2, 6 stage 3 
FEV1 (L) 1.8 ± 0.89 
Post-bronchodilator FEV1 (% predicted) 72.1 ± 11.8 
Reversibility (%) 5.6 ± 4.2 
FEV1/FVC ratio 60.2±5.2 
Smoking status 2 current, 6 ex 
Smoking history (pack-years) 35.3 ± 16.2 
  
Sputum Cell Counts  
Macrophages (% total) median % (range) 7 (4.8 – 33.4) 
Neutrophils (% total) median % (range) 91.9 (39.7 – 93.1) 
Lymphocytes (% total) median % (range) 1 (0 – 1.7) 
Eosinophils (% total) median % (range) 0.6 (0 – 25.7) 
 591 
592 
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TABLE 2. 593 
PCR primers for MKP-1 mRNA analysis 594 
 595 
 
 
Forward 
 
Reverse 
 
MKP-1 
 
5’-GTACATCAAGTCCATCTGAC 
 
5’ GGTTCTTCTAGGAGTAGACA 
 
GAPDH 
 
5’- GAAGGTGAAGGTCGGAGTC 
 
5’- GAAGATGGTGATGGGATTTC 
 596 
597 
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FIGURE LEGENDS 598 
Figure 1. Validation of the quality of nuclear extract and GR-GRE binding. 599 
The quality of nuclear extracts (panel A) was determined by Western Blotting. Fluticasone 600 
propionate (FP)-induced GR-GRE binding (panel B) and FP-induced GR nuclear localisation (panel 601 
C) were assessed in U937 monocytes. Results represent the mean ± SEM of 3 independent 602 
experiments. *p<0.05 denotes statistical significance vs. untreated cells. 603 
 604 
Figure 2. Confocal laser images of GR subcellular localisation in sputum macrophages 605 
following corticosteroid (FP 500µg) treatment. (panels A, D) 4’, 6-diamidino-2-phenylindole 606 
dihydrochloride (DAPI) staining (blue channel); (panels B, E) cytoplasmic and nuclear GR 607 
immunostaining (green channel); (panels C, F) overlay of panels A and B.  608 
 609 
Figure 3. Effect of inhaled salmeterol (SLM) and fluticasone propionate (FP) on GR-GRE 610 
binding in nuclear extracts from induced sputum macrophages (panel A) and PBMCs (panel B). 611 
Mean ± SEM absorbance values of GR-GRE binding are shown 60 minutes post-inhalation of 612 
treatment, where numeric values are inhaled drug doses in micrograms. n = 8 subjects.  .  613 
*p<0.05 and **p<0.01 denote statistical significance between treatments. 614 
 615 
Figure 4.  Fffect of fluticasone propionate (FP, 10-9M) and salmeterol (SLM, 10-7M) on GR-GRE 616 
DNA binding in sputum macrophages from COPD patients ex vivo.  .  Mean ± SEM absorbance 617 
values of GR-GRE binding are shown. n = 5subjects. *p<0.05 denotes statistical significance 618 
between treatments. 619 
 620 
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Figure 5. Effect of fluticasone (FP, 10-9M) and salmeterol (SLM, 10-8M) on MKP-1 mRNA 621 
induction and GRE-luciferase activity in macrophage-like PMA-treated U937 cells in vitro.  (A) 622 
MKP-1 mRNA expression normalized with GAPDH (panel A) and the fold-increase in GR of 623 
stimulated vs. non stimulated cells (panel B) are shown. Results represent the mean ± SEM of 624 
three independent experiments. * p<0.05 and *** p<0.001 denote statistical significance 625 
between treatments. 626 
 627 
Figure 6. Effect of fluticasone propionate (FP) and salmeterol (SLM) on IL-1β-induced CXCL8 in 628 
macrophage-like U937 cells. Results represent the mean ± SEM of 8 independent experiments. 629 
*p<0.05 denotes statistical significance vs. FP (10-11M) and #p<0.01 denotes statistical 630 
significance vs. IL-1β stimulated.  631 
